A phase II trial of temsirolimus in second-line metastatic urothelial cancer. - Wikidata - wikimedia - TriplyDB

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

http://www.wikidata.org/entity/Q48463573

about

Muscle-invasive urothelial bladder cancer: an update on systemic therapy Targeting Hsp90 in urothelial carcinoma Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis New therapeutic targets in the management of urothelial carcinoma of the bladder Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention Targeted therapies in bladder cancer: an overview of in vivo research.Emerging drugs for urothelial (bladder) cancer.Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group.Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.The Rho GTPase signalling pathway in urothelial carcinoma.Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.miR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells.Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.

P2860

Q26775780-82596CBD-55E9-403A-BD60-046DEE62B28D Q27023406-A55CCDC3-9372-4D2F-BEC6-4697FD33C9AE Q34993621-F03F5B73-3DFF-49F0-881B-37D57F785458 Q37108266-F0AF05DB-9E83-437D-B9CE-A01242097730 Q37305943-3A53BD1A-C97B-477A-9D07-E2D34FC7AA8B Q37527255-2BC401B4-B1BA-42A0-852F-3E4406009BA8 Q38590471-2DB73503-EEC6-4EEB-8B07-F9A272814D37 Q38677414-D723E02A-5221-4EB1-82BD-5E17BC06086C Q38779903-61A5B75F-3AC8-4DBA-922D-160D26698F3A Q46909057-8191506F-6C5F-412C-A345-BDA1F464210C Q47406507-BA3EF5B2-4F43-4D8E-8127-E7D1BAA63A29 Q48007361-FFF69C3C-3134-444B-A5E2-DF635FFCCB01 Q49081390-FF73A53B-8F3E-49E0-B64A-DB262072F52E Q49425667-84D5F056-640B-45B7-87B7-8AC177470078 Q49901067-68A5E44B-67D8-4819-8E4B-07C9E9DFE3E5

P2860

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

http://www.wikidata.org/entity/Q48463573

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

@en

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

@nl

type

label

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

@en

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

@nl

prefLabel

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

@en

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

@nl

P1433

Q48463573-E060F9B2-CF14-4576-A4C8-2349C37A8BFA

P1476

Q48463573-51BB81D2-E1AD-49A1-A996-C23D86E8373E

P2093

Q48463573-320DDA05-C818-4F49-A1C2-F1EA308C94A5

Q48463573-34767864-3C43-4905-A721-56AC87FD54F4

Q48463573-3E9E7F43-37A5-4BA7-BC8E-C2ED80D3A742

Q48463573-40AE3531-1F69-4D7F-BF1E-FBC36468BEA6

Q48463573-554CD2F0-8CCA-4171-BCF7-B0482BF8711A

Q48463573-6EE98790-9829-4361-B82B-B108AE3E6E43

Q48463573-8AA7EE79-5820-4442-A26C-5F918393A0BC

Q48463573-BBEB6A63-B217-4248-92B2-D594591E9D2C

Q48463573-F62C1DC1-D90C-49F3-A6FE-277DEDAD67C3

P2860

Q48463573-18911026-5728-4652-9879-328E8483F7A4

Q48463573-3975B8D7-7B4F-473A-BDCA-015C720D82A6

Q48463573-3CB830C8-514A-4A4F-8A28-6C34B62FEA58

Q48463573-479CC0CA-6EAB-46D8-B981-A3487EB9B16B

Q48463573-4A907E13-62C8-4036-8A60-E3172AD8A870

Q48463573-5BFCE8CC-4F4E-48AD-9F2D-A4A8FB9B6AE9

Q48463573-60AEDC42-2C67-44E5-8D89-419CC9CDA2C7

Q48463573-615EE372-0A4D-4B73-B350-83DF2D2E9D04

Q48463573-678F7DC0-7F9C-41A1-BFFA-BB4F0A6CAA97

Q48463573-774AEBDD-6FBB-4E1B-98F9-3269E2717FE9

P2888

Q48463573-AA7747C6-5C9D-426D-B0F2-2909E8976CD4

P304

Q48463573-33F56D16-D91F-4CE3-AF81-69DB4729645E

P31

Q48463573-C10DD075-8E57-496A-96BA-8E5500F2DF6A

P356

Q48463573-E305F12C-1D6A-482E-8EA6-7E569B24B1EC

P433

Q48463573-8ADDB02E-62FE-4F3C-8D74-C6CA10738935

P478

Q48463573-F5F18CD8-1779-44DC-8F7A-472D4C8E7706

P577

Q48463573-415DBB5E-AA68-4757-9B1B-F66B3772D974

P698

Q48463573-1D320C87-0C95-4678-B6C0-8DD9AAB90D8F

P921

Q48463573-4AEC8919-470E-41DC-AFF1-DBD0B114DCF9

P356

S12032-012-0216-X

P1433

Medical Oncology

P1476

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

@en

P2093

C Arndt

http://www.w3.org/2001/XMLSchema#string

C Eimer

http://www.w3.org/2001/XMLSchema#string

C Freitas

http://www.w3.org/2001/XMLSchema#string

C Heusch

http://www.w3.org/2001/XMLSchema#string

E Georgas

http://www.w3.org/2001/XMLSchema#string

H Gerullis

http://www.w3.org/2001/XMLSchema#string

S Kastenholz

http://www.w3.org/2001/XMLSchema#string

T H Ecke

http://www.w3.org/2001/XMLSchema#string

T Otto

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

Chemotherapy for metastatic or unresectable bladder cancer.

Second-line therapy in bladder cancer.

P2888

s12032-012-0216-x

P304

2870-2876

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-012-0216-X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22447503

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial